GGrantIndex
← Leaderboards

Bruce R Ksander

Massachusetts Eye And Ear Infirmary

Google Scholar ↗PubMed ↗ORCID ↗
$8,642,324
Attributed
$17,529,893
Total exposure
9
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$17,529,893 · 9

By mechanism

R01$10,932,806 · 6
R24$5,912,245 · 1
R21$450,313 · 1
P30$234,529 · 1

Top collaborators

Most similar at Massachusetts Eye And Ear Infirmary

Same institution · by research overlap

Others in their field

Top investigators on “Blindness”

Research focus

BlindnessVisionCellsChronicInflammationTissuesGenesPreventCorneaStem Cell PopulationIn VitroSkinStem CellsAllogenicCell Surface ProteinsNatural RegenerationNeovascularizationCorneal StromaLimbalAutologousBilateralCorneal EpitheliumCorneal DiseasesMonoclonal Antibodies

Grant awards (33)

ABCB5-positive stem cells for LSCD therapy$761,966
R01 · FY2025 · EY
In vivo epigenetic reprogramming of retinal ganglion cells in aging mice with glaucoma$679,159
R01 · FY2025 · EY
ABCB5-positive stem cells for LSCD therapy$761,966
R01 · FY2024 · EY
Regulation of the neuroinflammatory response in autoimmune uveitis$425,000
R01 · FY2024 · EY · contact PI
ABCB5-positive stem cells for LSCD therapy$801,142
R01 · FY2023 · EY
Regulation of the neuroinflammatory response in autoimmune uveitis$425,000
R01 · FY2023 · EY · contact PI
Multipotent ABCB5-positive cell therapeutics for corneal disease$1,176,331
R24 · FY2022 · EY
Regulation of the neuroinflammatory response in autoimmune uveitis$412,250
R01 · FY2022 · EY · contact PI
Multipotent ABCB5-positive cell therapeutics for corneal disease$1,176,331
R24 · FY2021 · EY
Regulation of the neuroinflammatory response in autoimmune uveitis$425,000
R01 · FY2021 · EY · contact PI
Multipotent ABCB5-positive cell therapeutics for corneal disease$1,176,331
R24 · FY2020 · EY
ABCB5-positive stem cells for LSCD therapy$487,236
R01 · FY2020 · EY
Multipotent ABCB5-positive cell therapeutics for corneal disease$1,176,331
R24 · FY2019 · EY
ABCB5-positive stem cells for LSCD therapy$489,489
R01 · FY2019 · EY
Multipotent ABCB5-positive cell therapeutics for corneal disease$1,206,921
R24 · FY2018 · EY
ABCB5-positive stem cells for LSCD therapy$491,647
R01 · FY2018 · EY
ABCB5-positive stem cells for LSCD therapy$598,457
R01 · FY2017 · EY
ABCB5-positive stem cells for LSCD therapy$275,698
R01 · FY2017 · EY
ABCB5-positive stem cells for LSCD therapy$534,234
R01 · FY2016 · EY
ABCB5-positive stem cells for LSCD therapy$104,732
R01 · FY2016 · EY
sGCa1-deficient mice: a novel murine model of elevated IOP and glaucoma$202,835
R21 · FY2012 · EY
sGCa1-deficient mice: a novel murine model of elevated IOP and glaucoma$247,478
R21 · FY2011 · EY
IMMUNOBIOLOGY OF CORNEAL TRANSPLANTATION$428,227
R01 · FY2007 · EY · contact PI
IMMUNOBIOLOGY OF CORNEAL TRANSPLANTATION$430,637
R01 · FY2006 · EY · contact PI
IMMUNOBIOLOGY OF CORNEAL TRANSPLANTATION$441,000
R01 · FY2005 · EY
CELL MEDIATED IMMUNE RESPONSE TO INTRAOCULAR TUMORS$372,000
R01 · FY2003 · EY
CELL MEDIATED IMMUNE RESPONSE TO INTRAOCULAR TUMORS$348,000
R01 · FY2002 · EY
CORE--ANIMAL RESOURCE$134,676
P30 · FY2002 · EY
CELL MEDIATED IMMUNE RESPONSE TO INTRAOCULAR TUMORS$324,000
R01 · FY2001 · EY
CELL MEDIATED IMMUNITY TO OCULAR TUMORS$302,716
R01 · FY2001 · EY
CELL MEDIATED IMMUNE RESPONSE TO INTRAOCULAR TUMORS$319,350
R01 · FY2000 · EY
CELL MEDIATED IMMUNITY TO OCULAR TUMORS$293,900
R01 · FY2000 · EY
CORE--ANIMAL RESOURCE$99,853
P30 · FY2000 · EY